This site is intended for healthcare professionals. Not a healthcare professional? Visit Mill-Klinika

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

Results from a new post-hoc analysis of the landmark RE-LY®i trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin.